ReviewFrontiers in pharmacology2025
The therapeutic potential of cyanidin-3-O-glucoside relating to female reproductive health.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Natural Bioactive Compounds in Polycystic Ovary Syndrome: Properties, Molecular Mechanisms, and Therapeutic Potential.International journal of molecular sciences · 2026Review
- Impact of plant-based interventions on gynecological cancers: a narrative review of mechanistic interplays and clinical evidence.Frontiers in molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyanidin-3-O-glucoside (C3G), a dietary flavonoid found in berries, exhibits strong antioxidant, anti-inflammatory, and anticancer properties. It plays a role in female reproductive health by protecting ovarian cells from oxidative stress while inhibiting tumour growth and inducing apoptosis in ovarian and cervical cancer cells. C3G can modulate estrogen receptors, growth factors, and apoptosis- and angiogenesis-related pathways. Its antioxidant and anti-inflammatory properties may be beneficial in hormone-related reproductive disorders and in oncological conditions of reproductive organs, such as ovarian cancer. Beyond its anticancer effects, C3G may be able to mitigate reproductive disorders such as polycystic ovary syndrome (PCOS), although its low bioavailability and need for improved delivery methods pose challenges. C3G influences gut microbiota and enhances systemic antioxidant activity, too. This evidence-based study summarizes the biological effects of C3G, emphasizing its impact on female reproductive health, proposing its mechanism(s) of action, and potential clinical application. Future pre-clinical and clinical investigations are needed to determine C3G's effective dosages and assessment as a complementary or alternative therapy in gynecological oncology and reproductive health. Moreover, as many of these observations in the literature are based on large
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.